Selected engagements with the numbers up front. Cases are anonymized; the work and the results are real.
A top 20 global biopharma, a five-year portfolio plan, and an outcome 36 percent above pre-launch consensus.
Read the case →A global launch into a hyper-competitive therapeutic area, rehearsed until the organization was ready to win it.
Read the case →If your organization is launching a new therapy where failure is not an option, let's talk.
Contact us